Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Atteberry

Orthopaedic Surgery Council Bluffs, IA Medical Doctor

NPI 1629063508 CMS profile 694510

1 Edmundson Pl, Ste 500, Council Bluffs, IA 51503

Open in the dashboard

General payments

$8,213

90 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Atteberry of Council Bluffs, IA is reported in the CMS Open Payments database as having received $8,213 across 90 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $835 20
2024 General $653 9
2023 General $733 12
2022 General $2,766 9
2021 General $1,391 7
2020 General $406 12
2019 General $1,429 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Atteberry
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Atteberry were reported at $835. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Atteberry Orthopaedic Surgery median Middle half National median
2019 $1,429 $644 $140–$2,844 $163
2020 $406 $312 $75–$1,860 $114
2021 $1,391 $520 $117–$2,495 $132
2022 $2,766 $598 $128–$2,731 $149
2023 $733 $461 $128–$2,264 $160
2024 $653 $497 $134–$2,475 $164
2025 $835 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Conetic Solutions, Inc. $4,009 10 payments
  2. Stryker Corporation $1,379 32 payments
  3. RSW Medical Company, Inc. $703 2 payments
  4. Vericel Corporation $360 5 payments
  5. Arthrex, Inc. $307 5 payments
  6. DePuy Synthes Sales Inc. $235 5 payments
  7. Sanara MedTech Inc. $220 1 payment
  8. Smith+Nephew, Inc. $189 7 payments
  9. Zimmer Biomet Holdings, Inc. $150 3 payments
  10. Vertex Pharmaceuticals Incorporated $144 4 payments
  11. Other $517 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $4,284 4 payments
  2. Food and Beverage $3,929 86 payments
Products named General payments · program years 2019–2025
  1. MAKO $374 3 payments
  2. MACI $360 5 payments
  3. CellerateRx $220 1 payment
  4. OMEGA $202 5 payments
  5. NA $179 3 payments
  6. PRO $139 1 payment
  7. HemiCAP Shoulder $134 2 payments
  8. BIO4 $90 1 payment
  9. VITOSS $90 1 payment
  10. NEUROMATRIX $90 1 payment
  11. Other $1,896 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,156

Median for Orthopedic Surgery: 203

Drug cost

$11,169

Median for Orthopedic Surgery: $1,433

Branded share of claims

15.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 184 $4,789
Naproxen Generic 322 $2,031
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 96 $1,068
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 64 $919
Gabapentin Generic 79 $720
Methylprednisolone Generic 61 $477
Tramadol Hcl Generic 97 $373
Meloxicam Generic 156 $336
Cephalexin Generic 32 $180
Oxycodone Hcl Generic 17 $121

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$69,207

Of which drugs: $3,848

Medicare patients

205

Average age 75

Services billed

3,175

116 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Chronic kidney disease 31%
Diabetes 30%
Depression 27%
Ischemic heart disease 26%
COPD 21%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 34 2,240 $211
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 20 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record